Medtronic has just gained FDA approval for their next generation of insulin pump – the Minimed 770G hybrid closed loop system. The press release states that the “newest insulin pump system offers the company’s most advanced SmartGuard™ technology, as featured in the MiniMed 670G system, with the added benefits of smartphone connectivity and an expanded age indication to children as young as 2.”
According to the announcement from the FDA, the 770G system is “a bluetooth-enabled version of the previously approved MiniMed 670G System (with other modifications), is a hybrid closed loop system that works by measuring glucose levels in the body every five minutes and automatically adjusting insulin delivery by either administering or withholding insulin. The system includes: a sensor that attaches to the body to measure glucose levels under the skin; an insulin pump strapped to the body; and an infusion patch connected to the pump with a catheter that delivers insulin. While the device automatically adjusts insulin levels, users need to manually request insulin doses to counter carbohydrate consumption at mealtime.”
“We’re thrilled to be launching this new system as we understand how important these data sharing features are, particularly right now — with many individuals and families opting to see their doctors virtually via telehealth visits,” said Sean Salmon, executive vice president and president of the Diabetes Group at Medtronic. “As a parent, I understand very personally why connectivity is so important and I’m pleased we’ll be able to broaden access to hybrid closed loop therapy with the additional peace of mind caregivers need to ensure the well-being of their loved ones. This latest launch underscores my personal commitment to making life easier for people living with diabetes through the technologies we deliver.”
The device is not approved for use in children under 2 years old, or for people with diabetes who require less than eight units of insulin per day. More details will be released from Medtronic in the coming weeks.
